Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses high-response rates from both Selinexor and velcade and the combination of the two show synergy against myeloma at the 2017 American Society of Hematology.
High-Response Rates from both Selinexor and Velcade The combination of the two show synergy against Myeloma
